Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | A2B530 |
Trade Name | |
Synonyms | A-2B530|A 2B530|CEA Tmod |
Drug Descriptions |
A2B530 are autologous T-lymphocytes engineered to express a chimeric antigen receptor (CAR) targeting CEACAM5 (CEA), an LIR-1-based inhibitory receptor targeting HLA-A*02, and an shRNA targeting beta2 microglobulin, which potentially induce tumor cell killing and inhibition of tumor growth (Journal for ImmunoTherapy of Cancer 2022;10). |
DrugClasses | |
CAS Registry Number | NA |
NCIT ID | C199653 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
A2B530 | A2B530 | 0 | 1 |